MX2023014028A - Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos. - Google Patents

Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos.

Info

Publication number
MX2023014028A
MX2023014028A MX2023014028A MX2023014028A MX2023014028A MX 2023014028 A MX2023014028 A MX 2023014028A MX 2023014028 A MX2023014028 A MX 2023014028A MX 2023014028 A MX2023014028 A MX 2023014028A MX 2023014028 A MX2023014028 A MX 2023014028A
Authority
MX
Mexico
Prior art keywords
chk1
inhibitors
checkpoint kinase
methods
checkpoint
Prior art date
Application number
MX2023014028A
Other languages
English (en)
Inventor
Jacques Mauger
Anthony B Pinkerton
Stephen Todd Meyer
Yen Pham Hong Truong
Rachelle Janette Elsdon
Original Assignee
Boundless Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boundless Bio Inc filed Critical Boundless Bio Inc
Publication of MX2023014028A publication Critical patent/MX2023014028A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan compuestos y métodos para el tratamiento del cáncer. Los métodos incluyen administrar a un sujeto en necesidad una cantidad terapéuticamente efectiva de un inhibidor de Chk1 descrito en la presente.
MX2023014028A 2021-05-27 2022-05-26 Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos. MX2023014028A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163193990P 2021-05-27 2021-05-27
PCT/US2022/031141 WO2022251502A1 (en) 2021-05-27 2022-05-26 Checkpoint kinase 1 (chk1) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2023014028A true MX2023014028A (es) 2023-12-12

Family

ID=84229213

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014028A MX2023014028A (es) 2021-05-27 2022-05-26 Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos.

Country Status (12)

Country Link
US (2) US11707462B2 (es)
EP (1) EP4347582A1 (es)
JP (1) JP2024520481A (es)
KR (1) KR20240021188A (es)
CN (1) CN117715905A (es)
AU (1) AU2022282384A1 (es)
BR (1) BR112023024571A2 (es)
CA (1) CA3219348A1 (es)
IL (1) IL308759A (es)
MX (1) MX2023014028A (es)
TW (1) TW202313588A (es)
WO (1) WO2022251502A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022282384A1 (en) 2021-05-27 2023-12-14 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitors and uses thereof
TW202333680A (zh) * 2021-12-24 2023-09-01 日商住友製藥股份有限公司 具有二環性骨架之1h-吡唑-3-胺衍生物
WO2023230477A1 (en) * 2022-05-24 2023-11-30 Boundless Bio, Inc. Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof
WO2023226658A1 (en) * 2022-05-25 2023-11-30 Sperogenix Therapeutics Limited Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof
WO2024118564A1 (en) * 2022-11-29 2024-06-06 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitors and uses thereof
WO2024118596A1 (en) * 2022-11-29 2024-06-06 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501083A (ja) * 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
US20050209297A1 (en) * 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
PA8850801A1 (es) 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
PT3411036T (pt) * 2016-02-04 2022-02-21 Pharmaengine Inc Pirazóis 3,5-dissubstituídos úteis como inibidores da checkpoint quinase 1 (chk1) e as suas preparações e aplicações
JP2022542704A (ja) * 2019-08-01 2022-10-06 インテグラル バイオサイエンシーズ プライベート リミテッド キナーゼインヒビターとしての複素環式化合物およびその使用
CN112457306A (zh) * 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
CN111253370B (zh) 2020-03-24 2021-08-03 浙江大学 N-多取代吡啶-2-氨基嘧啶类衍生物及用途
WO2021253095A1 (en) * 2020-06-19 2021-12-23 Anaxis Pharma Pty Ltd Sulphonamide compounds
AU2021325905A1 (en) 2020-08-12 2023-04-13 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer
US20230025065A1 (en) * 2020-11-30 2023-01-26 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1h-pyrazol-3-amine derivative
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
AU2022282384A1 (en) 2021-05-27 2023-12-14 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitors and uses thereof

Also Published As

Publication number Publication date
US20230310423A1 (en) 2023-10-05
TW202313588A (zh) 2023-04-01
IL308759A (en) 2024-01-01
BR112023024571A2 (pt) 2024-02-06
CA3219348A1 (en) 2022-12-01
US11707462B2 (en) 2023-07-25
CN117715905A (zh) 2024-03-15
US20230026313A1 (en) 2023-01-26
KR20240021188A (ko) 2024-02-16
EP4347582A1 (en) 2024-04-10
AU2022282384A1 (en) 2023-12-14
JP2024520481A (ja) 2024-05-24
WO2022251502A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
MX2023014028A (es) Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos.
MX2023002248A (es) Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2020002646A (es) Inhibidores de enpp1 y su uso para el tratamiento del cancer.
EA202190630A1 (ru) Способы комбинированной терапии
MX2023011576A (es) Compuestos para la inhibicion de proteinas que contienen el dominio de pirina de la familia nlr 3 (nlrp3) y usos de estos.
MX2021009269A (es) Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
HK1120441A1 (en) Drugs for treatment of ovarian cancer
MX2014000130A (es) Procedimientos y composiciones para la inhibicion de resorcion osea.
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
WO2018102687A3 (en) Combination therapy for treating cancer
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022015900A (es) Inhibidores de alk2 para el tratamiento de la anemia.
MX2023010657A (es) Inhibidores de los retrotransposones largos intercalados del elemento 1 (line-1) para tratar enfermedades del sistema nervioso central (snc) y sistemicas.
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
MX2021013318A (es) Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
MX2021007565A (es) Composiciones y metodos para la terapia contra el cancer.
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
MX2021010560A (es) Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MX2020010556A (es) Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2021006210A (es) Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica.